1. Introduction

A wide variety of bacteria and fungi are found on the human skin. Although some skin microorganisms produce antibacterial peptides that inhibit invasion by pathogens or promote the integrity of cutaneous defenses by eliciting host immune responses, the normal microbiome can also cause several skin diseases.

Atopic dermatitis (AD) is a chronic disease that causes pruritus and involves cycles of remission and deterioration. AD is the result of dry hypersensitive skin. When the skin is dry, the protective barrier function of the cutaneous surface horny layer is compromised, and the skin readily develops dermatitis in response to various external stimuli, including skin microorganisms. Serum from almost all AD patients contains IgE antibodies against some skin microorganisms. For example, staphylococcal superantigen-specific IgE is present in the serum of AD patients, but not in the serum of healthy individuals. Normally, the weakly acidic condition of healthy skin prevents colonization by *Staphylococcus aureus*. However, in patients with AD, the skin pH is shifted toward neutrality, allowing *S. aureus* to grow and exacerbate AD.

In the cutaneous fungal microbiome, lipophilic yeasts of the genus *Malassezia* are the predominant species on human skin. As *Malassezia* species require lipids for growth, they preferentially colonize sebum-rich areas such as the head, face, and neck, as opposed to the limbs or trunk. Specific IgE antibody against *Malassezia* species is found in the serum of AD patients. Antifungal therapy improves the symptoms of AD by decreasing the level of *Malassezia* colonization, suggesting that these microorganisms also exacerbate AD. *Malassezia* species, unlike *S. aureus*, colonize both AD patients and healthy subjects. Currently, the genus *Malassezia* consists of 14 species. Of these, *M. globosa* and *M. restricta* have been detected in almost all AD patients, suggesting that these two *Malassezia* species play a significant role in AD. The level of specific IgE antibody against both species is greater than that against other *Malassezia* species.

This chapter discusses cutaneous fungi as an exacerbating factor in AD, focusing on:
- the fungal microbiome in patients with AD.
- immunological aspects of fungal colonization, and
- treatment with antifungal agents.
2. The fungal microbiome in patients with atopic dermatitis

2.1 Colonization by the fungus *Malassezia* in patients with atopic dermatitis

The lipophilic yeast *Malassezia* is the predominant fungus on human skin. Morphologically, these microorganisms are ovoid, elongate, and cylindrical (Fig. 1). Their genome is smaller than that of other fungi (Xu *et al.* 2007). As *Malassezia* species require lipids for growth, they preferentially colonize sebum-rich areas such as the head, face, or neck, rather than the limbs or trunk. Specific IgE antibodies against *Malassezia* are present in the serum of patients with AD, and antifungal therapy can improve the symptoms of AD by decreasing the degree of colonization by *Malassezia*; thus, this fungus is believed to be an exacerbating factor in AD (more details are provided in a later chapter). In contrast to *S. aureus*, *Malassezia* species colonize both AD patients and healthy individuals. In addition to AD, *Malassezia* species are responsible for seborrheic dermatitis, folliculitis, and pityriasis versicolor (Gupta *et al.* 2004; Ashbee 2007). Currently, 14 species are recognized within the genus *Malassezia* (Table 1), and five of these (*M. caprae*, *M. cuniculi*, *M. equina*, *M. nana*, and *M. pachydermatis*) show affinity for nonhuman animals.

<table>
<thead>
<tr>
<th>Host</th>
<th>Species</th>
<th>Species implicated in skin disease in human</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human associated species</td>
<td><em>Malassezia derratis</em></td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td><em>Malassezia furfur</em></td>
<td>SI</td>
</tr>
<tr>
<td></td>
<td><em>Malassezia globosa</em></td>
<td>AD, SD, PV</td>
</tr>
<tr>
<td></td>
<td><em>Malassezia japonica</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia obtusa</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia slooffiae</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia sympodialis</em></td>
<td>AD, SD</td>
</tr>
<tr>
<td></td>
<td><em>Malassezia restricta</em></td>
<td>AD, SD, PV</td>
</tr>
<tr>
<td></td>
<td><em>Malassezia yamatoensis</em></td>
<td></td>
</tr>
<tr>
<td>Nonhuman animal associated species</td>
<td><em>Malassezia caprae</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia cuniculi</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia equina</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia nana</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Malassezia pachydermatis</em></td>
<td></td>
</tr>
</tbody>
</table>

AD, atopic dermatitis; SD, seborrheic dermatitis; SI, systemic infection; PV, pityriasis versicolor

Table 1. Currently accepted *Malassezia* species

A number of epidemiological studies have been conducted during the past decade to elucidate the role of *Malassezia* as an exacerbating factor in AD. The first was carried out by Nakabayashi *et al.* (2000) in Japan and detected *M. furfur*, *M. globosa*, *M. sympodialis*, and *M.
slooffiae in 21.4, 14.3, 7.1, and 3.6% of samples from Japanese AD patients, respectively. A study conducted in Sweden in 2005 produced similar results (Sandström et al. 2005). However, a Canadian study by Gupta et al. (2001) reported the predominant species to be M. sympodialis, which was detected in 51.3% of the samples from AD patients. All of these studies were performed using culture-dependent methods. In all cases, scale samples were collected by an appropriate method, e.g., swabbing, scratching, or stripping, and were incubated in medium containing several types of fatty acids. The recovered microorganisms were identified based on biochemical or physiological characteristics, including assimilation of Tween compounds and esculin, catalase reaction, and maximum growth temperature (Guého-Kellermann 2010; Kaneko et al. 2007). However, culture-dependent methods may not provide accurate and reliable results for Malassezia. The efficiency of culturing Malassezia strains depends on the isolation medium used, and the growth of some species, such as M. obtusa and M. restricta, is slower than that of others.

To overcome the difficulties of culture-dependent methods, including scale sampling methods, culturing conditions, and isolation techniques, Sugita et al. (2001) developed the first molecular analytical method for Malassezia. For this method, scale samples are collected by stripping with medical transparent dressing, and skin Malassezia DNA is directly extracted from the dressing. The Malassezia microbiota is then analyzed by real-time PCR, specific detection by PCR with a species-specific primer, or an rRNA clone method (Sugita et al. 2011). Although more expensive than culture-dependent methods, a
molecular-based, non-culture approach appears to be the most reliable and appropriate for analysis of the skin Malassezia microbiota (Sugita et al. 2001; Morishita et al. 2006; Takahata et al. 2007a, 2007b; Tajima et al. 2008; Amaya et al. 2007). In all scale samples from AD patients, both M. globosa and M. restricta were detected by the molecular-based method, with the level of colonization by M. restricta being approximately 1.6 times that of M. globosa (Sugita et al. 2006a). Malassezia sympodialis was the second most predominant species (detected in 58% of the cases), and M. dermatitis, M. furfur, M. obtusa, and M. slooffiae were detected in less than 30% of the cases (Fig. 2). These results suggest that both M. globosa and M. restricta may significantly exacerbate AD.

Malassezia DNA was detected by nested PCR assay with species-specific primers

Fig. 2. Colonization frequency of Malassezia in the scale of patient with atopic dermatitis

Given that M. globosa and M. restricta commonly colonize both AD patients and healthy individuals, specific genotypes of these microorganisms may play a role in AD (Sugita et al. 2003, 2004, 2010). The fungal rRNA gene consists of four subunits: 5S, 5.8S, 18S (small), and 26S (large). Located between the subunits are an internal transcribed spacer (ITS) and an intergenic spacer (IGS). In M. globosa, the IGS is 444 to 454 bp long and has four short sequence repeats (SSRs), (CT1)$_n$ (CT2)$_n$ (CT3)$_n$ and (GT)$_n$, which occur at positions 29–49, 278–291, 380–485, and 242–267, respectively, in the IGS sequence of M. globosa strain CBS 7996. Alignments of IGS 1 sequences of two M. globosa strains are shown in Fig. 3. The number of (CT)$_n$ SSRs in the IGS 1 region is more variable in samples from healthy individuals than in those from AD patients. In samples from AD patients, the number of sequence repeats in the IGS 1 region
ranged from 4 to 11 for (CT1)n, 3 to 10 for (CT2)n, and 3 to 11 for (CT3)n, with 4 (CT1)n repeats in 50% of the samples, 8 (CT2)n in 60%, and 9–11 (CT3)n in 80%. For (GT)n, the respective numbers of repeats in 70–80% of the SSRs in the IGS 1 region were 9–11 in samples from AD patients and 15–19 in samples from healthy individuals. A phylogenetic tree constructed from 52 IGS 1 sequences is shown in Fig. 4. The tree consists of four major groups, which correspond to the sources of the samples (AD patients or healthy individuals). Two groups are from AD patients, and one is from healthy individuals. The remaining group included samples from both AD patients and healthy individuals. The IGS 1 sequences were more diverse in the samples from healthy individuals compared with AD patients. The IGS 1 sequence similarity was 94.5 ± 3.5% among the AD patient samples and 89.9 ± 3.5% among the samples from healthy individuals. The IGS 1 sequences of *M. restricta* are divided into two major groups, corresponding to AD patients and healthy individuals.

**Fig. 3. DNA sequences of the IGS 1 region of *M. globosa*.**

2.2 *Malassezia* colonization and severity of AD

The *Malassezia* microbiota of the skin is also associated with the severity of AD. Fifty-six adult neck and head AD patients (21 mild, 18 moderate, and 17 severe cases) and 32 healthy individuals were examined for skin *Malassezia* microbiota, using a real-time PCR assay (Kaga et al. 2011). The level of colonization by *Malassezia* was almost identical among the mild and moderate AD patients and the healthy individuals, while *Malassezia* colonization in the severe AD cases was approximately 2- to 5-fold that in the mild and moderate AD patients and healthy individuals (Fig. 5A). Two major species, *M. globosa* and *M. restricta*, accounted for more than 80% of all *Malassezia* colonization in AD patients of all severities, but their proportions differed with severity. In the mild and moderate cases, *M. restricta* predominated over *M. globosa* (*p* < 0.05), whereas the proportions of *M. globosa* and *M. restricta* were almost identical (*p* > 0.05) in the severe patients (Fig. 5B).
AD, patients with atopic dermatitis; HS, healthy subjects.

Fig. 4. Phylogenetic tree of *M. globosa* colonizing the skin surface of AD patients and healthy subjects based on DNA sequences of the IGS 1 region.

Fig. 5. Level of *Malassezia* colonization in patients with atopic dermatitis and in healthy individuals (A). Ratio of the two major *Malassezia* species, *M. globosa* and *M. restricta*, in patients with atopic dermatitis and in healthy individuals (B).

In a comprehensive analysis using an rRNA gene clone library method, Zhang *et al.* (2011) found that not only *Malassezia* but also the overall fungal microbiota differed according to AD severity. Their analysis of 3,647 clones of the fungal rRNA gene in scale samples from nine AD patients (3 mild, 3 moderate, and 3 severe cases) and 10 healthy individuals revealed 58 fungi and seven unknown phylotypes. *Malassezia* predominated, representing 63–86% of the clones identified from each subject. The number of clones had no noticeable relationship to disease severity, with the mild, moderate, and severe cases accounting for 67.8 ± 2.2, 70.7 ± 2.8, and 64.9 ± 1.8% of the clones, respectively. The study also confirmed
that both *M. globosa* and *M. restricta* were the predominant species regardless of disease severity, with a detection rate of 57.5–70.4% in all clones analyzed. However, the ratio of *M. globosa* to *M. restricta* in the mild and moderate cases (*M. restricta/M. globosa*: 3.1–3.4 in mild and 2.1–4.1 in moderate cases) differed from that in the severe cases (1.1–1.4). Figure 6 shows the phylogenetic distribution between AD patients and healthy individuals, based on principal coordinates analysis. Patients with mild or moderate symptoms of AD constituted a single cluster, and patients with severe disease formed a separate cluster. Similarly, the healthy individuals clustered independently.

![Figure 6](image_url)

Closed triangle, patients with mild symptoms; closed square, patient with moderate symptoms; closed circle, patients with severe symptoms; open circle, healthy individuals

Fig. 6. Principal coordinates analysis (PCA) score plot of the sequence profiles for the predominant skin fungi

Differences in microbiota are thought to be attributable to differences in the physiological condition of the skin between patients with AD and healthy subjects. For example, skin pH may change skin microbiota (Seidenari and Giusti, 1995). *Staphylococcus epidermidis* is present in the skin microbiota of healthy individuals, whereas *S. aureus* is not. The level of colonization by *S. aureus* increases according to the severity of AD. In contrast, the level of colonization by *S. epidermidis* decreases gradually with increasing AD severity. Healthy skin is weakly acidic, whereas the skin pH in patients with AD is near neutral, which facilitates invasion by exogenous microorganisms, including *S. aureus* (Higaki et al. 1999; Hoeger et al. 1992). The expression levels of antimicrobial peptides may also affect the fungal microbiota (Howell 2007). The antimicrobial peptides known as defensins and cathelicidins are deficient in the skin of AD patients, and thus the fungal microbiota should be different between AD patients and healthy individuals. Sebum is a growth medium for skin microorganisms and consists of squalene, cholesterol esters, wax esters, triglycerides, free fatty acids, cholesterol, ceramides, cholesterol sulfate, and phospholipids. Of these, the
proportion of ceramide 1, which is a carrier of linoleate and responsible for the water-barrier function of the skin, is significantly lower in patients with AD (Yamamoto et al. 1991). Therefore, the composition of sebum may also affect the fungal microbiota.

3. Immunological aspects of *Malassezia* colonization

3.1 *Malassezia* specific IgE antibody

Specific IgE antibodies against skin *Malassezia* are present in the serum of AD patients whereas no anti-*Malassezia* specific IgE antibody is found in the serum of healthy individuals (Sugita et al. 2001). Many studies have reported on anti-*Malassezia* specific IgE antibodies in AD patients (Zargari et al. 2003; Kato et al. 2006). Using an enzyme-linked immunosorbent assay (ELISA), Kato et al. (2006) quantified specific IgE antibodies against soluble proteins of eight *Malassezia* species in mechanically disrupted extracts of serum samples from AD patients. The level of IgE specific for *M. restricta* was greater than that against other *Malassezia* species (*M. dermatis*, *M. furfur*, *M. globosa*, *M. obtusa*, *M. pachydermatis*, *M. slooffiae*, and *M. sympodialis*) (Fig. 7); however, a competitive inhibition ELISA revealed that *M. restricta* contained species-specific as well as shared antigens.

\[ N=24 \]

Fig. 7. The species-specific IgE values of eight *Malassezia* species in sera from patients with atopic dermatitis determined using an ELISA.
The precise mechanisms by which *Malassezia* colonization induces IgE antibody production and the inflammatory cascades that lead to AD remain unclear. The presence of IgE antibodies has been implicated in the production of Th2-type cytokines such as interleukins (IL)-4, -5, -6, -10, and -13, the promotion of IgE antibody production, the differentiation of mast cells, and the growth, migration, and activation of eosinophils (Hamid et al. 1994; Leung et al. 2000; Chen et al. 2004). Keratinocytes, the major cell type in the epidermis, have roles in both skin structural and immunological defense (Esche et al. 2004; Albanesi et al. 2005). Keratinocytes produce a range of proinflammatory and immune cytokines in response to microorganisms and/or skin damage (Grone et al. 2002; Watanabe et al. 2001). A recent study has demonstrated that keratinocytes secrete several Th2-type cytokines that are critical in the pathogenesis of AD (Ishibashi et al. 2006). Cytokine secretion profiling by antibody array analysis has revealed that *M. globosa* and *M. restricta* induce the secretion of distinct Th2-type cytokines by human keratinocytes: *M. globosa* induces IL-5, IL-10, and IL-13 secretion, while *M. restricta* induces IL-4 secretion. These findings have been confirmed by cDNA microarray analysis showing that *M. globosa* and *M. restricta* upregulate the transcription of the IL-5 and IL-4 genes, respectively, in keratinocytes. These observations provide evidence of a possible relationship between *Malassezia* colonization and increased IgE production in AD. It is possible that *M. globosa* and *M. restricta* play a synergistic role in triggering a Th2-shifted humoral immune response in AD. Another important connection between *Malassezia* colonization and AD relates to the increased secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) and cutaneous T-cell-attracting chemokine (CTACK) by keratinocytes (Ishibashi et al. 2006). *Malassezia globosa* is capable of stimulating keratinocytes to secrete GM-CSF, which primarily contributes to the maintenance of the chronic inflammatory process in AD by enhancing the antigen-presenting capacity of Langerhans cells and dendritic cells (Witmer-Pack et al. 1987). *Malassezia restricta* induces the secretion of CTACK by keratinocytes. CTACK selectively attracts cutaneous lymphocyte antigen-positive memory T cells to inflammatory sites (Morales et al. 1999) and is upregulated in AD patients (Kakinuma et al. 2003). The above findings suggest the following possible mechanism by which *Malassezia* species induce an IgE-immune response in patients with AD: a skin barrier dysfunction facilitates skin penetration by colonized *Malassezia*, allowing interactions between *Malassezia* and epidermal Langerhans cells, dendritic cells, and keratinocytes, which subsequently present *Malassezia* antigens, thereby inducing an immune response. This may be augmented by keratinocyte-derived GM-CSF. *Malassezia*-stimulated keratinocytes produce Th2 cytokines, including IL-4 and IL-13, which may in turn stimulate B cells to undergo IgE class switching and produce *Malassezia*-specific IgE. In addition, keratinocyte-derived IL-5 may attract and locally activate eosinophils in lesions of AD.

### 3.2 Malassezia allergens

Many *Malassezia* allergens have been identified, including Mal f2-4, Mal s1, and Mal s5-13. Several researchers have attempted to produce recombinant *Malassezia* allergens (rMal s1 and rMal s5-11) for diagnostic purposes (Schmidt et al. 1997; Schmid-Grendelmeier et al. 2005, 2006; Limacher et al. 2007) (Table 2). Recently, proteomics analysis has been applied to identify major allergens of *M. globosa* (Ishibashi et al. 2009). The IgE-reactive component of *M. globosa*, with a molecular mass of 42 kDa and designated as MGp42, has been identified by two-dimensional immunoblotting and partially sequenced by matrix-assisted laser desorption ionization time of flight mass spectrometry with post-source decay of the peptide digest. The
full-length cDNA encoding MGp42 has been cloned and sequenced by the rapid amplification of cDNA ends method. MGp42 exhibits properties similar to those of heat shock protein (hsp) family members, and evidence indicates that MGp42 may be a cleavage product of intact HSP70. However, no IgE cross-reactivity has been observed between MGp42 and recombinant human HSP70, suggesting that the epitopes of MGp42 recognized by serum IgE of AD patients are masked by steric hindrance in the presence of intact HSP70 and become exposed as a result of conformational changes during HSP70 cleavage.

<table>
<thead>
<tr>
<th>Allergens</th>
<th>Function</th>
<th>Species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mala s1</td>
<td>Unknown</td>
<td>M. sympodialis</td>
<td>Schmidt et al. 1997</td>
</tr>
<tr>
<td>Mala f2</td>
<td>peroxisomal protein</td>
<td>M. furfur</td>
<td>Yasueda et al. 1998</td>
</tr>
<tr>
<td>Mala f3</td>
<td>peroxisomal protein</td>
<td>M. furfur</td>
<td>Yasueda et al. 1998</td>
</tr>
<tr>
<td>Mala f4</td>
<td>Malate dehydrogenase</td>
<td>M. furfur</td>
<td>Onishi et al. 1999</td>
</tr>
<tr>
<td>Mala s5</td>
<td>peroxisomal protein</td>
<td>M. sympodialis</td>
<td>Hemmann et al. 1997</td>
</tr>
<tr>
<td>Mala s6</td>
<td>Cyclophilin</td>
<td>M. sympodialis</td>
<td>Hemmann et al. 1997</td>
</tr>
<tr>
<td>Mala s7</td>
<td>Unknown</td>
<td>M. sympodialis</td>
<td>Weichel et al. 2002</td>
</tr>
<tr>
<td>Mala s8</td>
<td>Unknown</td>
<td>M. sympodialis</td>
<td>Weichel et al. 2002</td>
</tr>
<tr>
<td>Mala s9</td>
<td>Unknown</td>
<td>M. sympodialis</td>
<td>Weichel et al. 2002</td>
</tr>
<tr>
<td>Mala s10</td>
<td>Heat shock protein</td>
<td>M. sympodialis</td>
<td>Lindborg et al. 1999</td>
</tr>
<tr>
<td>Mala s11</td>
<td>MnSOD</td>
<td>M. sympodialis</td>
<td>Lindborg et al. 1999</td>
</tr>
<tr>
<td>Mala s12</td>
<td>GMC oxidoreductase</td>
<td>M. sympodialis</td>
<td>Rasool et al. 2000</td>
</tr>
<tr>
<td>Mala s13</td>
<td>Thioredoxin</td>
<td>M. sympodialis</td>
<td>Limacher et al. 2007</td>
</tr>
</tbody>
</table>

Table 2. Malassezia allergens

4. Treatment with antifungal agents

4.1 Anti-Malassezia IgE in the serum of AD patients

Skin prick tests positive for Malassezia antigen and specific IgE antibodies have been demonstrated in head and neck AD (HANAD) patients. A delayed-type hypersensitivity to Malassezia antigen also seems to play a role. Of 33 HANAD patients, 79% were prick-test positive for Malassezia antigen, but only 44% of 22 AD patients without head and neck involvement were prick-test positive (Kieffer et al. 1990). Rokugo et al. (1990) found that 71% of 35 AD patients who were prick-test positive for Malassezia antigen also demonstrated delayed hypersensitivity to Malassezia antigen in 64% of 118 AD patients. The presence of anti-Malassezia IgE antibody has been demonstrated in several studies (Table 3). The frequency of Malassezia specific IgE antibody in serum was higher in AD patients with head and neck dermatitis than without. For example, Bayrou et al. (2005) found IgE antibodies against Malassezia antigen in 100% of 106 HANAD patients, but in only 28% of 25 AD patients without head and neck involvement. Total IgE levels were also significantly higher in the AD group with head and neck dermatitis (mean, 2,823 kU/L) than without (546 kU/L).
Table 3. Malassezia IgE antibodies in sera of patient with atopic dermatitis

<table>
<thead>
<tr>
<th>Authors</th>
<th>Patients</th>
<th>Production of anti-Malassezia specific IgE antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Devos and Valk, 2000</td>
<td>HANAD</td>
<td>100% (n=22)</td>
</tr>
<tr>
<td></td>
<td>Non-HANAD</td>
<td>14% (n=22)</td>
</tr>
<tr>
<td>Johansson et al. 2003</td>
<td>HANAD</td>
<td>55% (n=98)</td>
</tr>
<tr>
<td></td>
<td>Non-HANAD</td>
<td>19% (n=33)</td>
</tr>
<tr>
<td>Jensen-Jarolim et al. 1992</td>
<td>HANAD</td>
<td>68% (n=80)</td>
</tr>
</tbody>
</table>

There was also a significant correlation between the level of Malassezia specific IgE antibody and clinical severity criteria, as reflected by the SCORAD index ($p < 0.0001$, $r^2 = 0.55$), whereas total IgE showed only a slight correlation with severity criteria ($p < 0.001$, $r^2=0.29$). No correlation was found between age or gender, and specific or total IgE. Based on prick-test results and specific IgE antibody levels, treatment of HANAD patients with antifungal agents has been recommended for the previous two decades.

### 4.2 Susceptibility of Malassezia to drug treatment

Compared with the plethora of antibacterial agents, only a small number of antifungal agents are available, which limits the treatment options for HANAD. Ketoconazole and itraconazole are highly effective in vitro (Sugita et al. 2005, Miranda et al. 2007, Sancak et al. 2005, Velegraki et al. 2004). In a large-scale study using 125 strains of 11 Malassezia species, all of the Malassezia species were highly susceptible to both itraconazole and ketoconazole, with minimum inhibitory concentrations (MICs) ranging from 0.016 to 0.25 mg/ml; approximately 80% of the strains had a MIC of $\leq 0.03$ mg/ml (Sugita et al. 2005). This efficacy is not specific to these species, but applies to all members of the genus Malassezia. To our knowledge, no resistant strain has been detected. Ketoconazole and itraconazole are chemically classified as azole compounds, but other azole agents, fluconazole, voriconazole, and terbinafine, cannot inhibit the growth of Malassezia.

A calcineurin inhibitor, topical tacrolimus, is widely used to treat AD. This compound had antifungal activity against half of the known Malassezia strains, with MICs of 16–32 mg/mL (Sugita et al. 2005). The immunosuppressive drugs cyclosporine and tacrolimus target calcineurin and are also toxic to Candida albicans and Cryptococcus neoformans (Cruz et al. 2001). A combination of either ketoconazole or itraconazole and tacrolimus had a synergistic effect against Malassezia strains, based on a fractional inhibitory index of 0.245 to 0.378. These observations follow earlier reports on the effectiveness of a combination of tacrolimus and fluconazole against C. albicans and C. neoformans strains. The combination of topical tacrolimus and an azole agent can simultaneously treat AD and reduce the number of exacerbating Malassezia cells colonizing the skin surface. Although the synergistic mechanism of this combination is not known, Maesaki et al. (1998) demonstrated that tacrolimus increases the intracellular concentration of the azole agent in C. albicans. This observation may provide the basis for future clinical trials of these agents aimed at reducing the number of Malassezia cells colonizing the skin of AD patients (more details are provided in the following section).
<table>
<thead>
<tr>
<th>Authors</th>
<th>Drug</th>
<th>Study design</th>
<th>Number of patients</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bäck et al. 1995</td>
<td>Ketoconazole</td>
<td>Open-label study</td>
<td>20 AD patients</td>
<td>200 mg daily for 2 months and 200 mg twice weekly for further 3 months.</td>
</tr>
<tr>
<td>Broberg and Faergemann, 1995</td>
<td>Ketoconazole shampoo</td>
<td>Randomized double-blind placebo-controlled study</td>
<td>53 HANAD patients</td>
<td>Group A: miconazole-hydrocortisone cream and ketoconazole shampoo for 6 weeks Group B: hydrocortisone cream and placebo shampoo for 6 weeks</td>
</tr>
<tr>
<td>Bäck and Bartosik, 2001</td>
<td>Ketoconazole</td>
<td>Randomized double-blind placebo-controlled study</td>
<td>29 HANAD patients with specific IgE antibodies to Malassezia</td>
<td>Group A: 200 mg ketoconazole daily for 3 months Group B: placebo for 3 months</td>
</tr>
<tr>
<td>Ikezawa et al. 2004</td>
<td>Itraconazole</td>
<td>Randomized double-blind crossover study</td>
<td>34 AD patients with positive RAST to Malassezia</td>
<td>Group A: 100 mg daily of itraconazole and lactobacillus preparation for 8 weeks and lactobacillus preparation alone for further 8 weeks Group B: Lactobacillus preparation alone for 8 weeks and 100 mg daily of itraconazole and lactobacillus preparation for additionally 8 weeks</td>
</tr>
<tr>
<td>Svejgaard et al. 2005</td>
<td>Itraconazole</td>
<td>Randomized double-blind placebo-controlled study</td>
<td>53 HANAD patients</td>
<td>Group A: 200 mg itraconazole for 7 days Group B: 400 mg itraconazole for 7 days Group C: placebo</td>
</tr>
</tbody>
</table>

Table 4. Treatment for ketoconazole or itraconazole in HANAD patients

4.3 *Ketoconazole and itraconazole in AD treatment* (Table 4)

A relationship between *Malassezia* and AD was first suggested by Clemmensen and Hjorth (1983), who demonstrated that oral ketoconazole was efficacious in adult HANAD patients with positive prick tests for *Malassezia*. A study of 20 AD patients with positive radioallergosorbent test results for *Malassezia* showed that treatment with oral ketoconazole...
improved clinical scores and reduced the levels of Malassezia specific IgE, particularly in the head and neck area (Bäck et al. 1995). However, in a double-blind study with 53 HANAD patients, no difference in the clinical score was detected between those treated with miconazole-hydrocortisone cream and ketoconazole shampoo and those treated with hydrocortisone cream and placebo shampoo, although the ketoconazole group showed decreased Malassezia colonization (Broberg and Faergemann 1995). In another randomized double-blind placebo-controlled study comparing treatment with 200 mg ketoconazole daily versus placebo for 3 months in 29 HANAD patients with specific IgE antibodies to Malassezia, the clinical score decreased in both groups, and the improvement was correlated with the use of topical steroids in the control group, but not in the ketoconazole group (Bäck and Bartosik 2001).

A number of studies have also been conducted with itraconazole. In one study, 53 HANAD patients were divided into three groups that received 200 mg itraconazole, 400 mg itraconazole, or placebo daily (Svejgaard et al. 2004). The study included a 7-day treatment period and a follow-up period of 105 days. At days 7 and 14, a significant improvement was observed in the SCORAD of the head and neck area in the groups given 400 and 200 mg itraconazole daily. At day 14, a comparison among all three groups showed a significant improvement in the SCORAD of the head and neck area in the 200 mg itraconazole group compared with the placebo group. A randomized double-blind crossover study was also conducted (Ikezawa et al. 2004). One group was treated with a combination of itraconazole (100 mg daily) plus a conventional Lactobacillus preparation for 8 weeks, followed by the Lactobacillus preparation alone for 8 weeks. The other group received the Lactobacillus preparation alone for 8 weeks, followed by itraconazole (100 mg daily) plus Lactobacillus for 8 weeks. In both groups, a decrease in the dose or strength of concomitant topical steroids was observed at the end of the treatment course with itraconazole, and improvements in the eosinophil count, serum IgE, and fungi-specific IgE were found after the administration of itraconazole.

Itraconazole appears to be a promising treatment option for HANAD patients who do not respond to conventional therapeutic approaches. To optimize the selection of patients most likely to respond to itraconazole treatment, the levels of Malassezia colonization of the skin and specific IgE antibody should be evaluated.

5. Acknowledgment

This study was supported in part by a research grant from the Japan Society for the Promotion of Science (TS), a research grant for “High-Tech Research Center Project” from the Ministry of Education, Culture, Sports, Science, and Technology (TS).

6. References


Atopic Dermatitis is a common disease characterized by inflamed, itching and dry skin. This relapsing allergic disorder has complex etiology and shows a remarkably high clinical heterogeneity which complicates the diagnosis and clinical management. This book is divided into 4 sections. The first section (Disease Etiology) describes some of the physiological mechanisms underlying Atopic Dermatitis, including alterations in the immune system and the skin-barrier function. The important role of host-microorganism interactions on the pathophysiology of Atopic Dermatitis is discussed in the second section (Microorganisms in Atopic Dermatitis). An overview of the clinical diagnostic criteria and the disease management protocols commonly used is given in the third section (Diagnosis and Clinical Management). The last section (New Treatments) describes new therapeutic approaches that are not widely used but are currently being studied due to preliminary evidence showing a clinical benefit for Atopic Dermatitis.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: